PD-1 inhibitor

This page covers all PD-1 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1 (Programmed Death-1), PD-1, PD-1 (Programmed Death Receptor-1).

Targets

PD-1 (Programmed Death-1) · PD-1 · PD-1 (Programmed Death Receptor-1) · PD-L1 · EGFR and MET

Marketed (10)

• immunotherapy with Nivolumab · Taipei Medical University WanFang Hospital · Oncology
  Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.
• Tislelizumab + radiotherapy · First Affiliated Hospital Xi'an Jiaotong University · Oncology
  Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses, and is combined with radiotherapy to enhance local and systemic tumor control.
• Cemiplimab-Rwlc · H. Lee Moffitt Cancer Center and Research Institute · Oncology
  Cemiplimab-Rwlc is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
• "MAX-40279-01" and "Toripalimab" · Maxinovel Pty., Ltd. · Oncology
  Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
• Vevye® · Baylor College of Medicine · Oncology
  Vevye is a monoclonal antibody that targets and inhibits the PD-1 receptor.
• Tislelizumab + platinum-based chemotherapy · Fujian Cancer Hospital · Oncology
  Tislelizumab blocks PD-1 on T cells to restore anti-tumor immunity, combined with platinum chemotherapy to enhance cytotoxic effects against cancer cells.
• PD-1 Monoclonal Antibody · Peking University People's Hospital · Oncology
  This monoclonal antibody binds to PD-1 on T cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses.
• Short-term Sintilimab · Shanghai Jiao Tong University School of Medicine · Oncology
  Sintilimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
• Actilitio® · Centro de Atencion e Investigacion Medica · Oncology
  Actilitio is a monoclonal antibody that targets the PD-1 receptor.
• K8 · Michelle Abou-Jaoude · Oncology
  K8 is a monoclonal antibody that targets the PD-1 receptor.

Phase 3 pipeline (160)

• placebo /IBI112 · Innovent Biologics (Suzhou) Co. Ltd. · Oncology
  IBI112 is an anti-PD-1 monoclonal antibody.
• Placebo to Pembrolizumab · Merck Sharp & Dohme LLC · Oncology
  Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.
• (D) DWC202207 · Daewoong Pharmaceutical Co. LTD. · Oncology
  DWC202207 is a drug that targets the PD-1 receptor.
• AD-223C · Addpharma Inc. · Oncology
  AD-223C is a small molecule that targets the PD-1 receptor.
• AG2304T · Ahn-Gook Pharmaceuticals Co.,Ltd · Oncology
  AG2304T is a small molecule targeting the PD-1 receptor.
• Placebo matching dostarlimab · Tesaro, Inc. · Oncology
  Dostarlimab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer cells.
• Camrelizumab plus chemo-radiotherapy · Sun Yat-sen University · Oncology
  Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses, combined with chemotherapy and radiotherapy for synergistic cancer cell killing.
• Concurrent PD-1 antibody · Sun Yat-sen University · Oncology
  A PD-1 antibody that blocks the PD-1 checkpoint protein on T cells, allowing the immune system to recognize and attack cancer cells.
• Pembrolizumab biosimilar · Laboratorio Elea Phoenix S.A. · Oncology
  This biosimilar blocks PD-1 on immune cells to restore anti-tumor immunity by preventing tumor cells from suppressing T-cell responses.
• Pembrolizumab (K) · Merck Sharp & Dohme LLC · Oncology
  Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, preventing tumor cells from evading immune attack.
• Pembrolizumab IV · Merck Sharp & Dohme LLC · Oncology
  Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, preventing tumor cells from evading immune attack.
• Treatment taken · Assistance Publique - Hôpitaux de Paris · Oncology
  This drug works by inhibiting the PD-1 receptor, which plays a key role in the immune system's ability to recognize and attack cancer cells.
• Experimental arm (CON): · University College, London · Oncology
  This drug targets the PD-1 receptor to inhibit cancer cell growth.
• ATGC-110 · ATGC Co., Ltd. · Oncology
  ATGC-110 is a small molecule that targets the PD-1 receptor.
• AD-221B · Addpharma Inc. · Oncology
  AD-221B is a small molecule that targets the PD-1 receptor.
• IBI308 · Innovent Biologics (Suzhou) Co. Ltd. · Oncology
  IBI308 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• IBI112 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Oncology
  IBI112 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• Y-3 for injection · Beijing Tiantan Hospital · Oncology
  Y-3 for injection is a monoclonal antibody that targets the PD-1 receptor.
• SYH2053injection · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Oncology
  SYH2053 is a monoclonal antibody targeting PD-1.
• SYSA1901 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Oncology
  SYSA1901 is a monoclonal antibody targeting PD-1.
• Camrelizumab Plus Chemotherapy · Jiangsu HengRui Medicine Co., Ltd. · Oncology
  Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses.
• US-sourced YERVOY® · Shanghai Henlius Biotech · Oncology
  YERVOY is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.
• Tislelizumab Injection · Nanjing Leads Biolabs Co.,Ltd · Oncology
  Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of immune cells, to inhibit the immune system's attack on cancer cells.
• ONO-4538 · Ono Pharmaceutical Co. Ltd · Oncology
  ONO-4538 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• guideline-recommended SoC · Shanghai East Hospital · Oncology
  This drug works by inhibiting the PD-1 receptor, which plays a key role in the immune system's ability to recognize and attack cancer cells.
• JS002 · Shanghai Junshi Bioscience Co., Ltd. · Oncology
  JS002 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses.
• Keytruda-EU · Sandoz · Oncology
  Keytruda (pembrolizumab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.
• PD-1inhibitor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Oncology
  A PD-1 inhibitor blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer.
• SM-1 · Sequential Medicine Ltd · Oncology
  SM-1 is a small molecule that targets the PD-1 receptor.
• PAXG · Associazione Italiana per lo Studio del Pancreas · Oncology
  PAXG is a drug that targets the PD-1 receptor.
• PF-06462700 · Pfizer · Oncology
  PF-06462700 is a small molecule that targets the PD-1 receptor.
• TAR-200 · Janssen Research & Development, LLC · Oncology
  TAR-200 is a monoclonal antibody targeting the PD-1 receptor.
• Sintilimab Combined With Docetaxel Monotherapy · Ye jinjun · Oncology
  Sintilimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.
• US-Keytruda® · Bio-Thera Solutions · Oncology
  US-Keytruda is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• Camrelizumab and Chemotherapy · Yue He, MD · Oncology
  Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, used in combination with chemotherapy to enhance cancer cell killing.
• Classic treatment · Sherief Abd-Elsalam · Oncology
  This drug works by inhibiting the PD-1 receptor, which is involved in the immune system's response to cancer cells.
• TNM002 · Zhuhai Trinomab Pharmaceutical Co., Ltd. · Oncology
  TNM002 is a monoclonal antibody targeting PD-1.
• cMAB · European Organisation for Research and Treatment of Cancer - EORTC · Oncology
  cMAB is a monoclonal antibody targeting the PD-1 receptor.
• VVZ-149 Injections · Vivozon, Inc. · Oncology
  VVZ-149 Injections is a monoclonal antibody that targets the PD-1 receptor.
• Nivolumab or pembrolizumab · Asan Medical Center · Oncology
  These drugs block the PD-1 checkpoint protein on immune cells, allowing the immune system to recognize and attack cancer cells.

Phase 2 pipeline (30)

• D10NS · MemorialCare · Oncology
  D10NS is a drug that targets the PD-1 receptor.
• JSKN016 injection · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Oncology
  JSKN016 injection is a monoclonal antibody targeting PD-1.
• BMS-986165 Dose B · Bristol-Myers Squibb · Oncology
  BMS-986165 is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells.
• Anti-PD1 Monoclonal Antibody · City of Hope Medical Center · Oncology
  Inhibits PD-1 receptor
• BGC20-0582 · Boston Scientific Corporation · Oncology
  BGC20-0582 is a drug that targets the PD-1 receptor.
• ASLAN003 · ASLAN Pharmaceuticals · Oncology
  ASLAN003 is a monoclonal antibody targeting the PD-1 receptor.
• Pembrolizumab after randomization · Intergroupe Francophone de Cancerologie Thoracique · Oncology
  PD-1 inhibitor
• ABO1020 · Suzhou Abogen Biosciences Co., Ltd. · Oncology
  ABO1020 is a monoclonal antibody targeting PD-1.
• Delayed Maintenance treatment · GlaxoSmithKline · Oncology
  This drug targets the PD-1 receptor to suppress cancer cell growth.
• BMS-790052 · Bristol-Myers Squibb · Oncology
  BMS-790052 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune responses.
• HLX208 · Shanghai Henlius Biotech · Oncology
  HLX208 is a monoclonal antibody targeting PD-1.
• Envafolimab plus Gemcitabine&Cisplatin · 3D Medicines (Sichuan) Co., Ltd. · Oncology
  Envafolimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell activation and anti-tumor immune responses.
• CM338 Injection · Keymed Biosciences Co.Ltd · Oncology
  CM338 Injection is a monoclonal antibody targeting the PD-1 receptor.
• Flexyn2a · LimmaTech Biologics AG · Oncology
  Flexyn2a is a monoclonal antibody that targets the PD-1 receptor.
• Anti-PD-L1 Monoclonal Antibody · City of Hope Medical Center · Oncology
  Anti-PD-L1 Monoclonal Antibody works by blocking the PD-L1 protein, allowing the immune system to attack cancer cells.
• 6MW3211 · Mabwell (Shanghai) Bioscience Co., Ltd. · Oncology
  6MW3211 is a monoclonal antibody targeting PD-1.
• AB103 · Atox Bio Ltd · Oncology
  AB103 is a monoclonal antibody targeting the PD-1 receptor.
• BC006 · Dragonboat Biopharmaceutical Company Limited · Oncology
  BC006 is a monoclonal antibody targeting the PD-1 receptor.
• ABBV-399 · SWOG Cancer Research Network · Oncology
  ABBV-399 is a PD-1 inhibitor, a type of immunotherapy that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells more effectively.
• Biological analyses · Hospices Civils de Lyon · Oncology
  This drug targets the PD-1 receptor to modulate the immune system.
• BMS-986231 · Bristol-Myers Squibb · Oncology
  BMS-986231 is an anti-PD-1 monoclonal antibody.
• BMS-986504 · Bristol-Myers Squibb · Oncology
  BMS-986504 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance immune response against cancer cells.
• 2014-ALC-919-US · Veloce BioPharma LLC · Oncology
  This drug targets the PD-1 receptor to modulate the immune response.
• DA-EPOCH-R followed by Nivolumab · Stichting Hemato-Oncologie voor Volwassenen Nederland · Oncology
  DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, followed by Nivolumab, a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.
• Pembrolizumab - 8 cycle · QuantumLeap Healthcare Collaborative · Oncology
  PD-1 inhibitor
• GSK Biologicals' 208136, new formulation · GlaxoSmithKline · Oncology
  This drug targets the PD-1 receptor to modulate the immune response.
• ES014 · Elpiscience (Suzhou) Biopharma, Ltd. · Oncology
  ES014 is a monoclonal antibody targeting PD-1.
• Amivantamab SC · Janssen Research & Development, LLC · Oncology
  Amivantamab SC is a fully human bispecific antibody that targets and blocks the activity of the EGFR and MET receptors.
• Additional Cycle of Pembrolizumab · Ismail Gögenur · Oncology
  Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.
• CP-547,632 · Pfizer · Oncology
  CP-547,632 is a small molecule inhibitor of the PD-1 receptor.